Sign Up to like & get
recommendations!
2
Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34532
Abstract: KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 (PD-L1)-positive, advanced non-small cell lung cancer (NSCLC), with most patients enrolled in mainland China. Eligible…
read more here.
Keywords:
pembrolizumab docetaxel;
docetaxel previously;
keynote 033;
previously treated ... See more keywords